GT Biopharma Inc (GTBP)
GT Biopharma Inc (NASDAQ: GTBP) is a clinical-stage biopharmaceutical company focused on developing and commercializing immuno-oncology therapies built around its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager, or Dual Targeting TriKE, platforms. Its development pipeline includes GTB-3650, a phase 1 candidate being studied for CD33-positive myeloid leukemias, GTB-5550, a phase 1 dose-escalation basket trial candidate targeting B7-H3 in advanced solid tumors, and GTB-7550, a preclinical program being evaluated for lupus and other autoimmune disorders. The company, which was formerly known as OXIS International, changed its name to GT Biopharma in July 2017. Incorporated in 1965, it is based in San Francisco, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GTBP
|
$0.44
|
25.2% Upside
|
Undervalued
|
$3
|
759.6% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 14, 2026
|
-0.3x
|
1.7x
|
—
|
12.297 M
|
3.628 M
|
0.0%
|
92.8%
|
-102.2
|
-0.8%
|
35.6%
|
